Page last updated: 2024-12-05

hexafluoroisopropanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,1,1,3,3,3-hexafluoropropan-2-ol : An organofluorine compound formed by substitution of all the methyl protons in propan-2-ol by fluorine. It is a metabolite of inhalation anesthetic sevoflurane. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13529
CHEMBL ID1231750
CHEBI ID63104
SCHEMBL ID199
MeSH IDM0041478

Synonyms (85)

Synonym
unii-3d632gyq50
ec 213-059-4
3d632gyq50 ,
chebi:63104 ,
CHEMBL1231750
2-propanol, 1,1,1,3,3,3-hexafluoro-
NCIOPEN2_001854
1,1,1,3,3,3-hexafluoro-2-propanol
1,1,1,3,3,3-hexafluoropropan-2-ol
ethanol,2,2-trifluoro-1-(trifluoromethyl)-
bis(trifluoromethyl)methanol
1,1,3,3,3-hexafluoro-2-propanol
hexafluoro-2-propanol
920-66-1
hexafluoroisopropyl alcohol
2,2-trifluoro-1-(trifluoromethyl)ethanol
2-propanol,1,1,3,3,3-hexafluoro-
wln: fxffyqxfff
2h-hexafluoroisopropanol
1,1,3,3,3-hexafluoroisopropanol
1,1,3,3,3-hexafluoroisopropyl alcohol
nsc-96336
nsc96336
hexafluoroisopropanol ,
hfip
einecs 213-059-4
ccris 6043
nsc 96336
ethanol, 2,2,2-trifluoro-1-(trifluoromethyl)-
2,2,2-trifluoro-1-(trifluoromethyl)ethanol
ai3-29336
1,1,1,3,3,3-hexafluoroisopropyl alcohol
1,1,1,3,3,3-hexafluoroisopropanol
brn 1841007
1,1,1,3,3,3-hexafluoro-2-propanol, >=99%
1,1,1,3,3,3-hexafluoro-2-propanol, >=99.5%
inchi=1/c3h2f6o/c4-2(5,6)1(10)3(7,8)9/h1,10
CFH ,
1,1,1,3,3,3-hexafluoro-isopropanol
FT-0690752
H0424
AKOS003791253
1,1,1,3,3,3-hexafluoroisopropane
1,1,1,3,3,3-hexafluoropropanol
2h-hexafluoro-2-propanol
1,1,1,3,3,3-hexafluoro propan-2-ol
hexafluoro isopropanol
1,1,1,3,3,3-hexafluoropropanol-2
1 1 1 3 3 3-hexafluoroisopropanol
1,1,1,3,3,3-hexafluoro-2-hydroxypropane
1,1,1,3,3,3-hexafluoro-2-propanol high purity grade 99.95+%
FT-0605913
sevoflurane impurity c [ep impurity]
hexafluoro-2-propanol, 1,1,1,3,3,3-
BP-21416
H1793
SCHEMBL199
(cf3)2choh
1,1,1,3,3,3-hexafluoro isopropanol
1,1,1,3,3,3-hexafluoro-propan-2-ol
hexafluorisopropanol
cf3ch(oh)cf3
Q-101270
mfcd00011651
F9994-0607
2-propanol,hexafluoro-(8ci,9ci)
DTXSID1022134
2h-perfluoro-2-propanol
1,1,1,3,3,3-hexafluoro-2-propanol (peptide grade)
SR-01000944926-1
sr-01000944926
1,1,1,3,3,3-hexafluoro-2-propanol, for gc derivatization, >=99.8%
1,1,1,3,3,3-hexafluoro-2-propanol, puriss., >=99.0% (gc)
1,1,1,3,3,3-hexafluoro-2-propanol glass distilled, derivatization grade
BCP05614
AS-19154
Q1123466
CS-0017220
qmlakmytrjqrmh-uhfffaoysa-n
adinbsizwlzkpo-uhfffaoysa-n
EN300-20423
D77965
1,1,1,3,3,3-hexafluoropropan-2-ol [for hplc]
hexafluoroisopropano
Z104478118

Research Excerpts

Overview

Hexafluoroisopropanol (HFIP) is a tri-fluorinated metabolites of volatile anesthetics. It has modulatory effects on inflammation that have been observed mainly in cell culture experiments.

ExcerptReferenceRelevance
"Hexafluoroisopropanol (HFIP) is a tri-fluorinated metabolites of volatile anesthetics and has modulatory effects on inflammation that have been observed mainly in cell culture experiments."( Hexafluoroisopropanol decreases liver ischemia-reperfusion injury by downregulation of high mobility group box-1 protein.
D'Albuquerque, LAC; Figueira, ERR; Galvao, FHF; Jukemura, J; Lanchotte, C; Nahas, SC; Rocha-Filho, JA; Urner, M; Vintimilla Moscoso, A; Ximenes, JLS, 2022
)
2.89
"Hexafluoroisopropanol (HFIP) is a nonpolar organic solvent that is often used to prepare β-amyloid peptide (Aβ) samples. "( Use-dependent inhibition of glycine-activated chloride current in rat neurons by β-amyloid peptide pretreated with hexafluoroisopropanol.
Bukanova, JV; Solntseva, EI, 2017
)
2.11

Effects

Hexafluoroisopropanol (HFIP) has been widely used as a counter anion in the mobile phase for ion-pairing reversed-phase liquid chromatography/mass spectrometry (IP-RP-LC/MS) analysis of oligonucleotides.

ExcerptReferenceRelevance
"Hexafluoroisopropanol (HFIP) has been widely used as a counter anion in the mobile phase for ion-pairing reversed-phase liquid chromatography/mass spectrometry (IP-RP-LC/MS) analysis of oligonucleotides. "( The role of fluoroalcohols as counter anions for ion-pairing reversed-phase liquid chromatography/high-resolution electrospray ionization mass spectrometry analysis of oligonucleotides.
Gong, L; Liu, R; Liu, Z; Ruan, Y, 2019
)
1.96
"Hexafluoroisopropanol (HFIP) has been widely used as an acidic modifier for mobile phases for liquid chromatography-mass spectrometry (LC-MS) analysis of oligonucleotides ever since the first report of its use for this purpose. "( The Role of Fluorinated Alcohols as Mobile Phase Modifiers for LC-MS Analysis of Oligonucleotides.
Bartlett, MG; Basiri, B; Murph, MM; van Dongen, WD; van Hattum, H, 2017
)
1.9
"Hexafluoroisopropanol (HFIP) has been widely used to dissolve Aβ and other amyloidogenic peptides."( Hexafluoroisopropanol induces self-assembly of β-amyloid peptides into highly ordered nanostructures.
Chaudhary, N; Nagaraj, R; Pachahara, SK; Subbalakshmi, C, 2012
)
2.54

Treatment

ExcerptReferenceRelevance
"Hexafluoroisopropanol pretreatment caused toxicity while, ammonium hydroxide treated Aβ42 induced cell proliferation in both C."( Pretreatment of chemically-synthesized Aβ42 affects its biological activity in yeast.
Caine, JM; Macreadie, IG; Porzoor, A, 2014
)
1.12

Pharmacokinetics

ExcerptReferenceRelevance
" A classical three compartments pharmacokinetic model developed for the study of environmental contaminants was fitted to the breath data."( Post-operative elimination of sevoflurane anesthetic and hexafluoroisopropanol metabolite in exhaled breath: pharmacokinetic models for assessing liver function.
Catania, N; Comite, C; Di Francesco, F; Fuoco, R; Ghimenti, S; Onor, M; Pleil, JD; Stiegel, MA; Trivella, MG, 2013
)
0.64
" Kinetic Pro (Wgroupe, France) was used for pharmacokinetic analysis."( Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients.
Bazin, JE; Biboulet, C; Bourdeaux, D; Constantin, JM; Houze, P; Launay, JM; Legrand, M; Lenoire, A; Mebazaa, A; Perbet, S; Pereira, B; Plaud, B; Sadoune, M; Sautou, V, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" With the ability to control the release of drug dosage locally within the spinal cord, drug-eluting microfibrous patches demonstrate the importance of appropriate local release-kinetics of rolipram, proving their usefulness as a therapeutic platform for the study and repair of SCI."( Drug-eluting microfibrous patches for the local delivery of rolipram in spinal cord repair.
Beattie, MS; Bresnahan, JC; Downing, TL; Farmer, DL; Lee, AL; Li, S; Nout, Y; Wang, A; Yan, ZQ, 2012
)
0.38
" This is especially important in the case of pediatric patients, and dose-response relationships require studies using pharmacokinetic-pharmacodynamic modeling."( A highly sensitive method for the simultaneous UHPLC-MS/MS analysis of clonidine, morphine, midazolam and their metabolites in blood plasma using HFIP as the eluent additive.
Aro, R; Herodes, K; Kipper, K; Lutsar, I; Metsvaht, T; Standing, JF; Veigure, R, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (281)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (1.78)18.7374
1990's30 (10.68)18.2507
2000's88 (31.32)29.6817
2010's139 (49.47)24.3611
2020's19 (6.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.81 (24.57)
Research Supply Index5.67 (2.92)
Research Growth Index5.39 (4.65)
Search Engine Demand Index76.32 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (1.40%)5.53%
Reviews6 (2.10%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.35%)0.25%
Other275 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]